Tetraphase Pharmaceuticals (NASDAQ:TTPH)‘s stock had its “overweight” rating reiterated by Piper Jaffray Companies in a research report issued on Friday, The Fly reports. They currently have a $4.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $6.00. Piper Jaffray Companies’ price objective would suggest a potential upside of 207.69% from the stock’s current price.
A number of other equities analysts have also issued reports on the company. Robert W. Baird reissued a “buy” rating and set a $3.00 price target on shares of Tetraphase Pharmaceuticals in a report on Monday, January 7th. B. Riley initiated coverage on Tetraphase Pharmaceuticals in a report on Friday, January 4th. They set a “buy” rating and a $3.00 price target on the stock. Finally, Zacks Investment Research raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 23rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $4.54.
Shares of TTPH stock opened at $1.30 on Friday. The stock has a market cap of $66.50 million, a price-to-earnings ratio of -0.49 and a beta of 2.99. Tetraphase Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $4.49.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Thursday, March 14th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.40). Tetraphase Pharmaceuticals had a negative return on equity of 65.89% and a negative net margin of 432.40%. As a group, sell-side analysts forecast that Tetraphase Pharmaceuticals will post -1.39 EPS for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in TTPH. Paloma Partners Management Co purchased a new position in shares of Tetraphase Pharmaceuticals during the 4th quarter worth approximately $33,000. Gamco Investors INC. ET AL increased its stake in shares of Tetraphase Pharmaceuticals by 42.9% during the 4th quarter. Gamco Investors INC. ET AL now owns 50,000 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 15,000 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Tetraphase Pharmaceuticals during the 4th quarter worth approximately $69,000. Rhumbline Advisers increased its stake in shares of Tetraphase Pharmaceuticals by 40.6% during the 4th quarter. Rhumbline Advisers now owns 72,976 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 21,089 shares in the last quarter. Finally, Alambic Investment Management L.P. increased its stake in shares of Tetraphase Pharmaceuticals by 392.6% during the 3rd quarter. Alambic Investment Management L.P. now owns 87,704 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 69,900 shares in the last quarter. 44.12% of the stock is currently owned by hedge funds and other institutional investors.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Featured Story: What does EPS mean?
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.